Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 186 clinical trials
None
Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not …

remission
cancer
fludarabine
hematologic malignancy
methotrexate
  • 39 views
  • 15 Apr, 2021
  • 39 locations
None
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Primary Therapeutic Objectives: To …

lymphoma
vorinostat
idarubicin
cyclophosphamide
flow cytometry
  • 231 views
  • 02 Sep, 2021
  • 7 locations
None
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow …

filgrastim
mitoxantrone
cyclophosphamide
umbilical cord blood transplantation
cell transplantation
  • 12 views
  • 23 Jan, 2021
  • 5 locations
None
Trial of Bortezomib Cytarabine and Dexamethasone in Mantle Cell Lymphoma

The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of

dexamethasone
bortezomib
cytarabine
refractory mantle cell lymphoma
neutrophil count
  • 8 views
  • 21 Jan, 2021
None
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

This phase study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.

hematologic disorder
cytarabine/daunorubicin
serum bilirubin level
remission
cytarabine
  • 0 views
  • 01 Jul, 2021
  • 1 location
None
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia

This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.

myelodysplasia
cytarabine/daunorubicin
leukapheresis
hydrea
cytarabine
  • 0 views
  • 03 Jun, 2021
  • 1 location
None
Fludarabine Cytarabine and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come

  • 0 views
  • 06 Sep, 2021
  • 1 location
None
Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

We are evaluating the efficacy of the association of Low dose Cytarabine in association with Bortezomib in the treatment of patients diagnosed with high risk Myelodysplastic syndromes

cytarabine
remission
blood transfusion
  • 8 views
  • 07 Nov, 2020
  • 12 locations
None
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

cytarabine
lymphocytic leukemia
chronic myeloid leukemia
myeloid leukemia
  • 16 views
  • 17 Feb, 2021
  • 3 locations
None
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine Cytarabine G-CSF for Refractory or Relapsed AML

This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute myeloid leukemia.

  • 0 views
  • 29 Apr, 2021
  • 1 location